Background/Aim: Helicobacter pylori (H.pylori) – associated chronic gastritis is a risk factor of gastric cancer. Recently, standard triple-drug therapy has a low rate of  H.pylori eradication due to the resistance of drug, especially Clarithromycin resistance. This study aims to confirm effect of H.pylori eradication of sequential therapy (RA-RCT) and compare with the standard triple-drug therapy (RCT), addition to evaluating the improvement about histology of chronic gastritis after treatment. Patients/Methods: 84 chronic gastritis patients with H.pylori infection were included. These patients were divided into two groups: 42 patients were treated with sequential therapy (RA-RCT), 42 patients were treated with standard triple-drug therapy (RCT) during 10 days. After 4 weeks, these patient were indicated endoscopy, check H.pyolori and biopsy to evaluate eradication H.pylori rate and histological improvement. Results: The eradication rate of H.pylori in sequential regimen group is 88.6% (per protocol: PP) and 73.8% (intention to treat: ITT). This rate is significant higher than the rates of the standard therapy: 62.5% (PP) and 50% (ITT) (p<0.05). There were no significant differences between two groups in side effects of drugs (25.0%: sequential therapy, 27.8% standard therapy). The improvement about inflammation grade at group successful H.pylori eradication is significant, while group with unsuccessful H.pylori eradication is no significant. Conclusion: sequential regimen has good efficacy, safety and good compliance. Further studies will be needed to evaluate the impact of H.pylori eradication by sequential therapy on pathology.